Voquezna denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for voquezna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Voquezna as Experimental — and Why That Denial Is Likely Wrong

Voquezna (vonoprazan) is FDA-approved for specific gastrointestinal indications including Helicobacter pylori infection (in combination regimens) and erosive esophagitis. An "experimental or investigational" denial issued after FDA approval is a factual error unless the specific use being prescribed falls outside the FDA-approved labeling.

If UHC's denial is based on an outdated policy that pre-dates the FDA approval, the denial should be reversed on the administrative record alone. If the denial reflects a truly off-label use, the appeal requires a different — but still viable — approach.

## Two Scenarios and How to Handle Each

Scenario A — The use is within the FDA-approved indication: This is a straightforward factual correction. Attach the FDA prescribing label, confirm the diagnosis code matches the approved indication, and request reversal. Most plans are required to cover FDA-approved drugs for their approved uses and cannot classify them as experimental.

Scenario B — The use is off-label: Many plans — and state laws for certain diagnoses — require coverage of off-label uses that are supported by peer-reviewed medical literature or recognized compendia (e.g., Micromedex, AHFS). Your prescriber's letter should cite the applicable guideline organization (e.g., ACG) and the compendium support for the use, without fabricating statistics.

## Your Appeal Rights

• Internal appeal (ERISA §503 / ACA): File within the deadline on the denial notice.
• External review (ACA §2719): After a final internal denial, you have approximately four months to request binding independent external review. IROs are experienced at distinguishing true investigational uses from FDA-approved or compendium-supported uses.
• State external review protections: Many states have specific protections for experimental/investigational denials that provide additional IRO access rights.

## Documentation to Gather

1. FDA prescribing label — Drugs@FDA current label; highlight the approved indication that matches the prescribed use. 2. Diagnosis code confirmation — from the prescriber's billing office, confirming the ICD-10 code matches the approved indication. 3. Prescriber medical-necessity letter — states the clinical indication, confirms FDA approval status, and (for off-label use) cites recognized compendia or guideline organization support. 4. UHC's medical policy for vonoprazan — obtain and attach it; note the effective date and compare it to the FDA approval date. 5. Clinical status documentation — records establishing the diagnosis and why treatment is needed now.

## Criteria-Mapping Structure

| Denial Basis | Rebuttal Evidence | |---|---| | Drug is investigational | FDA label with approval date; Drugs@FDA record | | Use not recognized | Guideline organization reference (ACG); compendium listing | | Policy predates approval | Date of UHC policy vs. FDA approval date |

An "experimental" denial overturned at external review carries a message to the plan: update the policy. Document your case thoroughly.